UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New Horizons for Precision Medicine in Biliary Tract Cancers

Cancer discovery, 2017-09, Vol.7 (9), p.943-962

2017

Volltextzugriff (PDF)

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

Hepatology (Baltimore, Md.), 2014-11, Vol.60 (5), p.1776-1782

2014

Volltextzugriff (PDF)

The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.e1036-e1049

2021

Volltextzugriff (PDF)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001435

2020

Volltextzugriff (PDF)

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Investigational new drugs, 2020-10, Vol.38 (5), p.1533-1539

2020

Volltextzugriff (PDF)

Abstract A071: AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A071-A071

2018

Volltextzugriff (PDF)

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2021-05, Vol.19 (5), p.541-565

2021

Volltextzugriff (PDF)

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4015-4015

2017

Volltextzugriff (PDF)

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

NPJ precision oncology, 2018-10, Vol.2 (1), p.22-22, Article 22

2018

Volltextzugriff (PDF)

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis

Cancer medicine (Malden, MA), 2018-07, Vol.7 (7), p.2934-2942

2018

Volltextzugriff (PDF)

AB014. S3A-3. Precision medicine on the horizon for cholangiocarcinoma

Hepatobiliary surgery and nutrition, 2019-03, Vol.8 (S1), p.AB014-AB014

Goyal, Lipika

2019

Volltextzugriff (PDF)

Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma

The oncologist (Dayton, Ohio), 2016-11, Vol.21 (11), p.1283-1285

2016

Volltextzugriff (PDF)

Relationship between hepatocellular carcinoma circulating tumor cells and tumor volume

Cancer convergence, 2018-07, Vol.2 (1), p.1-9, Article 2

2018

Volltextzugriff (PDF)

Paving a pathway for drug development in HER2-positive biliary tract cancer

The lancet oncology, 2021-09, Vol.22 (9), p.1204-1206

2021

Volltextzugriff (PDF)

Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9601-TPS9601

2022

Volltextzugriff (PDF)

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma

Cancer discovery, 2019-08, Vol.9 (8), p.1064-1079

2019

Volltextzugriff (PDF)

PS3-5 Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2

Annals of oncology, 2023-11, Vol.34, p.S1380-S1380

2023

Volltextzugriff (PDF)

A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4179-TPS4179

2023

Volltextzugriff (PDF)

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

The lancet. Gastroenterology & hepatology, 2021-10, Vol.6 (10), p.803-815

2021

Volltextzugriff (PDF)

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Clinical cancer research, 2020-12, Vol.26 (23), p.6158-6167

2020

Volltextzugriff (PDF)

Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.586-586

2023

Volltextzugriff (PDF)

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Nature medicine, 2024-08, Vol.30 (8), p.2377-2377

2024

Volltextzugriff (PDF)

PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.516-516

2024

Volltextzugriff (PDF)

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

Future oncology (London, England), 2020-10, Vol.16 (30), p.2375-2384

2020

Volltextzugriff (PDF)

A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS485-TPS485

2022

Volltextzugriff (PDF)

1 – 25 von 180

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(154)

Publikationsform

Sprache

Englisch
(180)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

New Horizons for Precision Medicine in Biliary Tract Cancers

Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions

The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Abstract A071: AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts

Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis

AB014. S3A-3. Precision medicine on the horizon for cholangiocarcinoma

Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma

Relationship between hepatocellular carcinoma circulating tumor cells and tumor volume

Paving a pathway for drug development in HER2-positive biliary tract cancer

Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma

PS3-5 Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIX-CCA2

A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement

Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC)

Aktive Filter

Suchergebnisse filtern